Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Naloxone
Accession Number
DB01183  (APRD00025)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as morphine, hydromorphone, methadone, heroin, or fentanyl are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils. If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like methamphetamine or cocaine, or benzodiazepines like lorazepam or diazepam.

Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion. Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies.

When injected intramuscularly (IM), naloxone acts within 3-5 minutes and can last from 30-60 minutes before its effects wear off. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening like they are for alcohol withdrawals. Administration of naloxone is therefore appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital.

Naloxone is also available within the combination product Suboxone with the opioid medication buprenorphine. Suboxone is used for the maintenance treatment of opioid dependence and addiction. When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine. The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.

Structure
Thumb
Synonyms
  • (−)-naloxone
  • 1-N-Allyl-14-hydroxynordihydromorphinone
  • 17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
  • Nalossone
  • Naloxona
  • Naloxone
  • Naloxonum
External IDs
EN 1530 Base
Product Ingredients
IngredientUNIICASInChI Key
Naloxone hydrochlorideF850569PQR357-08-4RGPDIGOSVORSAK-STHHAXOLSA-N
Naloxone hydrochloride dihydrate5Q187997EE51481-60-8TXMZWEASFRBVKY-IOQDSZRYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EvzioInjection, solution2 mg/0.4mLIntramuscular; SubcutaneousKaleo, Inc2016-10-19Not applicableUs
EvzioInjection, solution0.4 mg/1Intramuscular; SubcutaneousKaleo, Inc2014-04-032018-05-31Us
Injectable Naloxone HydrochlorideSolutionIntramuscular; Intravenous; SubcutaneousOmega Laboratories Ltd2016-08-05Not applicableCanada
Injectable Naloxone HydrochlorideSolutionIntramuscular; Intravenous; SubcutaneousOmega Laboratories LtdNot applicableNot applicableCanada
Naloxone HCl Injection - 0.4mg/ml USPLiquidIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Naloxone HCl Injection - 1mg/ml USPLiquidIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1995-12-31Not applicableCanada
Naloxone HydrochlorideInjection0.4 mg/1mLParenteralInternational Medication Systems, Limited2006-04-132006-04-13Us
Naloxone HydrochlorideInjection0.4 mg/1mLParenteralInternational Medication Systems, Limited2006-04-132006-04-13Us
Naloxone HydrochlorideInjection, solution0.02 mg/1mLIntramuscular; Intravenous; SubcutaneousHospira2006-05-112006-05-11Us
Naloxone HydrochlorideInjection, solution0.4 mg/1mLIntramuscular; Intravenous; SubcutaneousHospira2006-05-112006-05-11Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Naloxone HciInjection, solution0.4 mg/1mLIntramuscular; Intravenous; SubcutaneousHf Acquisition Co. Llc, Dba Health First2018-08-18Not applicableUs
Naloxone HydrochlorideInjection1 mg/1mLParenteralA-S Medication Solutions2001-06-01Not applicableUs
Naloxone HydrochlorideInjection1 mg/1mLParenteralCardinal Health2001-06-012019-11-30Us
Naloxone HydrochlorideInjection4 mg/1mLParenteralPhysicians Total Care, Inc.2001-08-012003-12-31Us
Naloxone HydrochlorideInjection, solution0.4 mg/1mLIntramuscular; Intravenous; SubcutaneousAkorn, Inc.2017-03-14Not applicableUs
Naloxone HydrochlorideInjection, solution0.4 mg/1mLIntramuscular; Intravenous; SubcutaneousA-S Medication Solutions2005-07-12Not applicableUs
Naloxone HydrochlorideInjection, solution0.4 mg/1mLIntramuscular; Intravenous; SubcutaneousGeneral Injectables and Vaccines, Inc.2018-06-12Not applicableUs
Naloxone HydrochlorideInjection1 mg/1mLParenteralRemedy Repack2015-03-102017-03-15Us
Naloxone HydrochlorideInjection1 mg/1mLParenteralGeneral Injectables & Vaccines, Inc2013-12-06Not applicableUs
Naloxone HydrochlorideInjection1 mg/1mLParenteralAmphastar Pharmaceuticals, Inc.1988-04-012013-01-10Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Buprenorphine/naloxoneNaloxone (2 mg) + Buprenorphine (8 mg)TabletSublingualActavis Pharma Company2017-09-28Not applicableCanada
Act Buprenorphine/naloxoneNaloxone (0.5 mg) + Buprenorphine (2 mg)TabletSublingualActavis Pharma Company2017-09-28Not applicableCanada
BunavailNaloxone hydrochloride dihydrate (0.3 mg/1) + Buprenorphine hydrochloride (2.1 mg/1)FilmBuccalBioDelivery Sciences International, Inc.2014-09-30Not applicableUs
BunavailNaloxone hydrochloride dihydrate (1 mg/1) + Buprenorphine hydrochloride (6.3 mg/1)FilmBuccalBioDelivery Sciences International, Inc.2014-09-30Not applicableUs
BunavailNaloxone hydrochloride dihydrate (0.7 mg/1) + Buprenorphine hydrochloride (4.2 mg/1)FilmBuccalBioDelivery Sciences International, Inc.2014-09-30Not applicableUs
Buprenorphine and NaloxoneNaloxone hydrochloride dihydrate (2 mg/1) + Buprenorphine hydrochloride (8 mg/1)TabletSublingualSun Pharmaceutical Industries, Inc.2017-07-18Not applicableUs
Buprenorphine and NaloxoneNaloxone (0.5 mg/1) + Buprenorphine (2 mg/1)TabletSublingualLannett Company, Inc.2016-09-19Not applicableUs
Buprenorphine and NaloxoneNaloxone hydrochloride dihydrate (3 mg/1) + Buprenorphine hydrochloride (12 mg/1)FilmBuccal; SublingualMylan Pharmaceuticals Inc.2019-02-20Not applicableUs
Buprenorphine and NaloxoneNaloxone (0.5 mg/1) + Buprenorphine hydrochloride (2 mg/1)Film, solubleBuccal; SublingualDr. Reddy’s Laboratories Inc.2018-06-14Not applicableUs
Buprenorphine and NaloxoneNaloxone hydrochloride (0.5 mg/1) + Buprenorphine hydrochloride (2 mg/1)Film, solubleBuccal; SublingualSandoz Inc2019-02-19Not applicableUs
International/Other Brands
Narcanti / Narcon
Categories
UNII
36B82AMQ7N
CAS number
465-65-6
Weight
Average: 327.3743
Monoisotopic: 327.147058165
Chemical Formula
C19H21NO4
InChI Key
UZHSEJADLWPNLE-GRGSLBFTSA-N
InChI
InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-10,17-dihydroxy-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
SMILES
OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O

Pharmacology

Indication

For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone and the narcotic-antagonist analgesics: nalbuphine, pentazocine and butorphanol. It is also indicated for the diagnosis of suspected acute opioid overdose. It may also be used as an adjunctive agent to increase blood pressure in the management of septic shock.

Associated Conditions
Pharmacodynamics

Naloxone is an opiate antagonist and prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. In the absence of narcotics or agonistic effects of other narcotic antagonists, it exhibits essentially no pharmacologic activity.

Mechanism of action

While the mechanism of action of naloxone is not fully understood, the preponderance of evidence suggests that naloxone antagonizes the opioid effects by competing for the same receptor sites, especially the mu-opioid receptor. Recently, naloxone has been shown to bind all three opioid receptors (mu, kappa and gamma) but the strongest binding is to the mu receptor.

TargetActionsOrganism
AMu-type opioid receptor
antagonist
Humans
ADelta-type opioid receptor
antagonist
Humans
AKappa-type opioid receptor
antagonist
Humans
NCyclic AMP-responsive element-binding protein 1
other/unknown
Humans
NEstrogen receptor alpha
antagonist
other/unknown
Humans
UToll-like receptor 4
inhibitor
Humans
ULiver carboxylesterase 1Not AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Tmax: 0.4mg IM injection = 0.38 hr Nasal spray (one 2mg spray) = 0.33 hr Nasal spray (one 4mg spray) = 0.50 hr

Cmax: 0.4mg IM injection = 0.88 ng/mL Nasal spray (one 2mg spray) = 2.91 ng/mL Nasal spray (one 4mg spray) = 4.83 ng/mL

Volume of distribution

Following parenteral administration naloxone hydrochloride is rapidly distributed in the body. Naloxone is also very lipophillic and easily crosses the blood-brain-barrier. It can also cross the placenta.

Protein binding

Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constituent but significant binding of naloxone also occurs to plasma constituents other than albumin.

Metabolism

Naloxone is hepatically metabolized and primarily undergoes glucuronidation to form naloxone-3-glucuronide.

Route of elimination

Urine (25%- 40% is excreted as metabolites within 6 hours)

Half life

0.4mg IM injection = 1.24 hr Nasal spray (one 2mg spray) = 1.85 hr Nasal spray (one 4mg spray) = 2.08 hr

Clearance
Not Available
Toxicity

LD50, IV administration, mouse = 150 ± 5 mg/kg; LD50, IV administration, rat = 109 ± 4 mg/kg;

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Naloxone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Naloxone.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Naloxone.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Naloxone.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Naloxone.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Naloxone.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Naloxone.
7-ethyl-10-hydroxycamptothecinThe metabolism of 7-ethyl-10-hydroxycamptothecin can be decreased when combined with Naloxone.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be decreased when combined with Naloxone.
AbacavirAbacavir may decrease the excretion rate of Naloxone which could result in a higher serum level.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Naloxone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference

Bianca Brogmann, Silke Muhlau, Christof Spitzley, "Pharmaceutical preparation containing oxycodone and naloxone." U.S. Patent US20050245556, issued November 03, 2005.

US20050245556
General References
  1. Link [Link]
External Links
Human Metabolome Database
HMDB0015314
KEGG Drug
D08249
KEGG Compound
C07252
PubChem Compound
5284596
PubChem Substance
46508816
ChemSpider
4447644
BindingDB
54795
ChEBI
7459
ChEMBL
CHEMBL80
Therapeutic Targets Database
DAP000097
PharmGKB
PA450586
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Naloxone
ATC Codes
A06AH04 — NaloxoneN02AA53 — Hydromorphone and naloxoneV03AB15 — NaloxoneN02AA55 — Oxycodone and naloxone
AHFS Codes
  • 28:10.00 — Opiate Antagonists
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePain NOS1
0CompletedTreatmentOpioid Use Disorders1
0CompletedTreatmentOpioid-use Disorder1
0RecruitingBasic SciencePain NOS1
0RecruitingDiagnosticAnoxic Brain Injury / Brain Death / Cardiac Arrest / Narcotic Intoxication / Sedative Intoxication1
1Active Not RecruitingBasic ScienceHealthy Volunteers1
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedNot AvailableSubstance, Addiction1
1CompletedBasic ScienceDrug Overdose1
1CompletedBasic ScienceHyperalgesia / Naloxone / Opioid Antagonist / Pain NOS1
1CompletedBasic ScienceIntestinal Obstruction1
1CompletedBasic ScienceOpiate Dependence1
1CompletedBasic ScienceOpioid Dependence1
1CompletedBasic ScienceSubstance, Addiction1
1CompletedOtherPain, Chronic1
1CompletedTreatmentAddictions / Opioid Dependence / Pain NOS1
1CompletedTreatmentBiological Availability1
1CompletedTreatmentCocaine-Related Disorders1
1CompletedTreatmentDrug Overdose1
1CompletedTreatmentDrug Overdose / Opioid-Related Disorders1
1CompletedTreatmentHIV Risk Behaviors / Substance-Related Disorders1
1CompletedTreatmentHealthy Males1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatitis C Viral Infection / Opioid-Related Disorders1
1CompletedTreatmentHepatitis C Virus (HCV) Infection1
1CompletedTreatmentHeroin Dependence / Opioid-Related Disorders1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Opioid Dependency1
1CompletedTreatmentOpiate Addiction1
1CompletedTreatmentOpioid Use Disorders2
1CompletedTreatmentOpioid-Related Disorders / Pain, Chronic1
1CompletedTreatmentOpioid-use Disorder2
1CompletedTreatmentPain NOS2
1CompletedTreatmentTreatment of Menopausal Hot Flashes1
1Not Yet RecruitingNot AvailableDrug Overdose / Opioid-Related Disorders1
1RecruitingPreventionIdiopathic Hypogonadotropic Hypogonadism1
1RecruitingTreatmentHeroin Dependence / Opioid Use Disorders1
1Unknown StatusTreatmentOpioid Overdose1
1, 2Active Not RecruitingPreventionHypoglycemia Unawareness / Type 1 Insulin-Dependent Diabetes Mellitus1
1, 2CompletedTreatmentChronic Pruritus1
1, 2CompletedTreatmentDepression / Major Depressive Disorder (MDD)2
1, 2CompletedTreatmentDrug Overdose1
1, 2CompletedTreatmentOpiate Addiction1
1, 2CompletedTreatmentOpioid Addiction / Opioid Dependence / Opioid Related Disorders1
1, 2CompletedTreatmentOpioid-Related Disorders1
1, 2RecruitingTreatmentDrug; Withdrawal Symptoms, Neonatal / Fetus and Newborn Affected by Other Maternal Medication / Withdrawal1
1, 2RecruitingTreatmentOpioid Dependence1
1, 2RecruitingTreatmentOpioid-use Disorder1
2CompletedBasic ScienceBMI >30 kg/m21
2CompletedBasic ScienceDrug Overdose1
2CompletedBasic ScienceHealthy Volunteers1
2CompletedBasic ScienceModerate to Severe Pain Due to Diabetic Polyneuropathy1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentBipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes / Schizoaffective Disorders1
2CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
2CompletedTreatmentGambling / Naloxone / Opioids / Spray1
2CompletedTreatmentInterstitial Cystitis / Pain NOS / Painful Bladder Syndrome (PBS)1
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentMalignancies / Occasional Constipation / Pain NOS1
2CompletedTreatmentMorphinan Opioid Overdose1
2CompletedTreatmentNausea / Pain NOS / Pruritus1
2CompletedTreatmentOccasional Constipation1
2CompletedTreatmentOpiate Dependence2
2CompletedTreatmentOpiate withdrawal symptoms / Opioid Dependence / Opioid Detoxification1
2CompletedTreatmentOpioid Dependence1
2CompletedTreatmentOpioid Induced Constipation (OIC) / Pain, Chronic1
2CompletedTreatmentOpioid Related Disorders1
2CompletedTreatmentOpioid Use Disorders1
2CompletedTreatmentOpioid-Related Disorders6
2CompletedTreatmentOpioid-Related Disorders / Substance-Related Disorders2
2Enrolling by InvitationTreatmentGambling Disorder / Naloxone / Opioid Antagonist / Pathological Gambling1
2Enrolling by InvitationTreatmentPain, Chronic1
2Enrolling by InvitationTreatmentSickle Cell Disorders1
2Not Yet RecruitingBasic SciencePain NOS / Placebo / Virtual Reality1
2Not Yet RecruitingTreatmentGambling Disorder / Gambling Urge / Naloxone / Opioid Antagonist / Pathological Gambling1
2Not Yet RecruitingTreatmentOpioids Use1
2RecruitingNot AvailableHealthy Volunteers1
2RecruitingBasic ScienceAutonomic Failure / Diabetes Mellitus (DM) / Hypoglycemia1
2RecruitingBasic ScienceCentral Nervous System Sensitization / Hyperalgesia / Pain NOS1
2RecruitingBasic ScienceHealthy Volunteers / Hyperalgesia / Inflammations, Endodontic / Pain, Acute / Sensitization, Central1
2RecruitingBasic ScienceMaternal Opioid Use Disorder / Opioid Exposed Infant1
2RecruitingPreventionPain, Neuropathic1
2RecruitingTreatmentHigh Dosage Buprenorphine1
2RecruitingTreatmentHyperalgesia1
2RecruitingTreatmentOpioid-use Disorder1
2RecruitingTreatmentType 1 Insulin-Dependent Diabetes Mellitus1
2TerminatedTreatmentDental Pain1
2TerminatedTreatmentOpioid-Related Disorders1
2Unknown StatusTreatmentPain, Chronic1
2, 3CompletedPreventionPruritus1
2, 3CompletedTreatmentBrain Death / Organ Donors / Transplantation, Lung1
2, 3CompletedTreatmentDependence, Cocaine1
2, 3CompletedTreatmentMalignant Pain / Non-malignant Pain1
2, 3CompletedTreatmentOccasional Constipation1
2, 3CompletedTreatmentOpioid Dependence2
2, 3Unknown StatusTreatmentBinge Eating Disorder (BED)1
3CompletedNot AvailableSubjects With Moderate to Severe, Chronic Nonmalignant Pain1
3CompletedBasic ScienceHeroin Dependence1
3CompletedBasic ScienceOpioid-Related Disorders1
3CompletedHealth Services ResearchHeroin Addiction1
3CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Alcohol Drinking / Alcohol-Related Disorders1
3CompletedTreatmentBack Pain Lower Back3
3CompletedTreatmentChronic Osteoarthritis1
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD)1
3CompletedTreatmentHeroin Dependence / Morphine Dependence / Substance Withdrawal Syndrome2
3CompletedTreatmentHeroin Dependence / Substance-Related Disorders1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
3CompletedTreatmentMalignancies / Pain NOS1
3CompletedTreatmentModerate to Severe Idiopathic RLS With Daytime Symptoms1
3CompletedTreatmentNon Cancer Pain1
3CompletedTreatmentOccasional Constipation / Pain NOS1
3CompletedTreatmentOpiate Dependence / Opioid-Related Disorders1
3CompletedTreatmentOpioid Dependence2
3CompletedTreatmentOpioid Dependence, on Agonist Therapy1
3CompletedTreatmentOpioid Dependence / Opioid Related Disorders1
3CompletedTreatmentOpioid Dependency1
3CompletedTreatmentOpioid Tolerance1
3CompletedTreatmentOpioid Use Disorders1
3CompletedTreatmentOpioid Use Disorders / Opioid-Related Disorders1
3CompletedTreatmentOpioid-Related Disorders1
3CompletedTreatmentPain NOS3
3CompletedTreatmentParkinson's Disease With Severe Pain1
3Not Yet RecruitingTreatmentDrug Abuse in Pregnancy / Drug withdrawal syndrome neonatal / Neonatal Opiate Withdrawal Syndrome / Opioid-Related Disorders / Pregnancy Related / Substance Abuse / Substance, Addiction1
3Not Yet RecruitingTreatmentDrug Abuse in Pregnancy / Drug withdrawal syndrome neonatal / Neonatal Opioid Withdrawal Syndrome / Opioid-Related Disorders / Pregnancy Related / Substance Abuse / Substance, Addiction2
3Not Yet RecruitingTreatmentOpiate withdrawal symptoms / Opioid-Related Disorders1
3Not Yet RecruitingTreatmentOpioids Use1
3RecruitingOtherOpioid Addiction1
3RecruitingTreatmentDrug Overdose / Substance Abuse1
3RecruitingTreatmentEpilepsies1
3RecruitingTreatmentHeroin Dependence1
3RecruitingTreatmentLymphoma, T-Cell, Cutaneous / Mycosis Fungoides (MF) / Sézary Syndrome1
3RecruitingTreatmentOpioid Induced Constipation (OIC)1
3TerminatedPreventionHuman Immunodeficiency Virus (HIV) Infections / Opioid-Related Disorders1
3TerminatedTreatmentOccasional Constipation / Pain NOS1
3Unknown StatusSupportive CareConstipation, Impaction, and Bowel Obstruction / Unspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentHip Arthroplasty / Knee Replacement Surgery / Spinal Anaesthesia1
3WithdrawnNot AvailableOpioid Dependence1
3WithdrawnTreatmentOpioid Dependence1
4CompletedPreventionRespiratory Depression1
4CompletedSupportive CareMalignancies1
4CompletedSupportive CarePain, Chronic1
4CompletedSupportive CareSpinal Disorders / Spinal Disorders Related Pain1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentBack Pain / Back Pain Lower Back / Pain, Neuropathic1
4CompletedTreatmentBack Pain / Osteoarthritis (OA)1
4CompletedTreatmentChronic Hepatitis C Infection With Hepatic Coma / Hepatic Failure / Hepatic Impairment1
4CompletedTreatmentEpidural Analgesia / Oral Oxycodone With/Without Naloxone / Postoperative Pain Management / Radical Cystectomy / Return of the Bowel Function1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentHeroin Dependence / Opioid Dependence / Substance-Related Disorders1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Substance Related Disorders1
4CompletedTreatmentMalignancies2
4CompletedTreatmentOccasional Constipation1
4CompletedTreatmentOpiate Addiction1
4CompletedTreatmentOpiate Dependence2
4CompletedTreatmentOpiate Dependence / Opiate-Related Disorders / Substance Abuse1
4CompletedTreatmentOpiate Dependence / Substance Dependence / Substance, Addiction1
4CompletedTreatmentOpiate Dependence / Substance, Addiction1
4CompletedTreatmentOpiate-Related Disorders1
4CompletedTreatmentOpioid Dependence, on Agonist Therapy1
4CompletedTreatmentOpioid Dependency1
4CompletedTreatmentOpioid Induced Pharyngeal and Esophageal Dysfunction1
4CompletedTreatmentOpioid Related Disorders / Postoperative pain1
4CompletedTreatmentOpioid Use Disorders1
4CompletedTreatmentPost Operative Pain1
4CompletedTreatmentSubstance, Addiction1
4CompletedTreatmentUnstable Angina Pectoris1
4Not Yet RecruitingOtherEvaluation of QTc Interval1
4Not Yet RecruitingTreatmentGeneral Surgery / Opioid-use Disorder / Pain, Acute1
4Not Yet RecruitingTreatmentOpioid Dependence1
4Not Yet RecruitingTreatmentOpioid Use Disorder, Mild / Opioid-use Disorder1
4RecruitingPreventionFusion of Spine / Ileus1
4RecruitingPreventionHypoglycemia / Hypoglycemia Unawareness / Type 1 Insulin-Dependent Diabetes Mellitus1
4RecruitingSupportive CareBack Pain Lower Back1
4RecruitingTreatmentDrug Overdose / Opioid-use Disorder1
4RecruitingTreatmentOccasional Constipation / Postoperative pain1
4RecruitingTreatmentOpioid Dependence1
4RecruitingTreatmentOpioid Use Disorders1
4RecruitingTreatmentOpioid-use Disorder2
4RecruitingTreatmentPain, Chronic1
4SuspendedBasic SciencePain NOS1
4TerminatedPreventionAnalgesia / Occasional Constipation1
4TerminatedTreatmentOpiate Addiction / Refractory Pains1
4TerminatedTreatmentPain NOS1
4Unknown StatusNot AvailableOpioid Induced Constipation (OIC) / Postoperative pain1
4Unknown StatusTreatmentDrug Overdose1
4Unknown StatusTreatmentOpioid Dependence1
4WithdrawnTreatmentOpiate Addiction1
4WithdrawnTreatmentPain, Chronic1
Not AvailableActive Not RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Opiate Addiction / Substance, Addiction1
Not AvailableActive Not RecruitingTreatmentPain, Chronic1
Not AvailableCompletedNot AvailableAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Opiate Dependence / Post Traumatic Stress Disorder (PTSD)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableNeoplasms / Pain, Cancer1
Not AvailableCompletedNot AvailableOpiate Dependence / Opioid-Related Disorders / Substance Abuse2
Not AvailableCompletedNot AvailableSevere Pain1
Not AvailableCompletedNot AvailableSevere, Chronic Pain1
Not AvailableCompletedBasic ScienceDrug Overdose1
Not AvailableCompletedBasic ScienceEndogenous and Esophageal Sensitivity1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedOtherHealthy Volunteers1
Not AvailableCompletedPreventionDrug Overdose / Opioid-Related Disorders / Substance Abuse / Substance, Addiction1
Not AvailableCompletedPreventionPain NOS1
Not AvailableCompletedPreventionPost-Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedSupportive CarePost-Operative Nausea and Vomiting (PONV) / Postoperative pain / Scoliosis1
Not AvailableCompletedSupportive CareUpper Extremity Trauma1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentHepatitis C Viral Infection / Heroin Dependence1
Not AvailableCompletedTreatmentMorphine Adverse Reaction1
Not AvailableCompletedTreatmentOpiate Addiction1
Not AvailableCompletedTreatmentOpiate withdrawal symptoms / Physical Dependence1
Not AvailableCompletedTreatmentOpioid-Related Disorders2
Not AvailableCompletedTreatmentPain NOS1
Not AvailableCompletedTreatmentPost-Op Complication1
Not AvailableNot Yet RecruitingNot AvailableOpioid Overdose1
Not AvailableRecruitingNot AvailableCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections / Opioid-use Disorder1
Not AvailableRecruitingNot AvailableOpioid Abuse1
Not AvailableRecruitingTreatmentOpioid-use Disorder1
Not AvailableSuspendedNot AvailableIschemia-Reperfusion Injury1
Not AvailableTerminatedNot AvailableBuprenorphine / Pain NOS1
Not AvailableTerminatedBasic ScienceBurning Mouth Syndrome / Temporomandibular Joint Dysfunction Syndrome1
Not AvailableTerminatedBasic ScienceHealthy Volunteers1
Not AvailableTerminatedTreatmentOpioid Use Disorders1
Not AvailableTerminatedTreatmentOpioid-Related Disorders1
Not AvailableUnknown StatusSupportive CarePain NOS1
Not AvailableWithdrawnBasic ScienceExperimental Pain Perception1
Not AvailableWithdrawnTreatmentOpiate Dependence1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amphastar Pharmaceuticals
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Endo Pharmaceuticals Inc.
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
  • Lake Erie Medical and Surgical Supply
  • Letco Medical Inc.
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Reckitt Benckiser Inc.
  • Southwood Pharmaceuticals
  • Stat Rx Usa
Dosage forms
FormRouteStrength
FilmBuccal
FilmBuccal; Sublingual
Film, solubleBuccal; Sublingual
Injection, solutionIntramuscular; Subcutaneous0.4 mg/1
Injection, solutionIntramuscular; Subcutaneous2 mg/0.4mL
LiquidIntramuscular; Intravenous; Subcutaneous
InjectionIntramuscular; Intravenous; Subcutaneous0.4 mg/1mL
InjectionParenteral0.4 mg/1mL
InjectionParenteral1 mg/1mL
InjectionParenteral4 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous0.02 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous0.4 mg/1mL
PowderNot applicable1 kg/1kg
SolutionIntramuscular; Intravenous; Subcutaneous
InjectionIntravenous0.02 mg/1mL
InjectionIntravenous0.4 mg/1mL
InjectionIntravenous1 mg/1mL
SprayNasal2 mg/0.1mL
SprayNasal4 mg/0.1mL
Spray, meteredNasal
TabletOral
Film, solubleSublingual
TabletSublingual
Tablet, extended releaseOral
Tablet, orally disintegratingSublingual
Prices
Unit descriptionCostUnit
Naloxone hcl powder70.9USD g
Naloxone 0.4 mg/ml vial7.07USD ml
Naloxone 0.4 mg/ml ampul4.78USD ml
Narcan 0.4 mg/ml ampul4.58USD ml
Naloxone 0.02 mg/ml vial0.84USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9205082No2015-12-082022-05-10Us
US7579019No2009-08-252020-01-22Us
US6159498No2000-12-122016-10-18Us
US9073933No2015-07-072025-03-30Us
US7674800No2010-03-092025-03-30Us
US7683072No2010-03-232025-03-30Us
US7674799No2010-03-092025-03-30Us
US8475832No2013-07-022030-03-26Us
US8603514No2013-12-102024-04-03Us
US8017150No2011-09-132023-02-13Us
US8425462No2013-04-232024-11-23Us
US8231573No2012-07-312028-11-25Us
US8016788No2011-09-132025-03-21Us
US8206360No2012-06-262027-02-27Us
US9238108No2016-01-192027-01-22Us
US8226610No2012-07-242029-04-10Us
US7918823No2011-04-052024-11-23Us
US8608698No2013-12-172024-11-23Us
US8021344No2011-09-202029-11-02Us
US8361029No2013-01-292024-11-23Us
US8313466No2012-11-202024-11-23Us
US7731690No2010-06-082025-01-15Us
US9278182No2016-03-082026-02-01Us
US7731686No2010-06-082026-06-01Us
US8926594No2015-01-062026-03-31Us
US7749194No2010-07-062028-10-30Us
US9056170No2015-06-162024-11-23Us
US7947017No2011-05-242028-03-12Us
US8939943No2015-01-272031-02-28Us
US8627816No2014-01-142032-02-04Us
US9022022No2015-05-052031-02-28Us
US8147866No2012-04-032027-07-23Us
US8703177No2014-04-222032-08-20Us
US8470361No2013-06-252030-05-22Us
US8454996No2013-06-042019-09-24Us
US8658198No2014-02-252027-12-03Us
US8940330No2015-01-272032-09-18Us
US9259421No2016-02-162032-09-18Us
US9168252No2015-10-272022-05-10Us
US9161937No2015-10-202022-05-10Us
US8969369No2015-03-032022-05-10Us
US9084729No2015-07-212022-05-10Us
US9283216No2016-03-152022-05-10Us
US9056051No2015-06-162022-05-10Us
US8846090No2014-09-302023-04-04Us
US6277384No2001-08-212018-12-22Us
US8822487No2014-09-022018-12-22Us
US8673355No2014-03-182018-12-22Us
US6696066No2004-02-242018-12-22Us
US8846091No2014-09-302023-04-04Us
US9211253No2015-12-152035-03-16Us
US9522919No2016-12-202025-03-30Us
US9517307No2016-12-132034-07-18Us
US9474869No2016-10-252031-02-28Us
US9522188No2016-12-202035-04-24Us
US9655843No2017-05-232027-07-23Us
US9439900No2016-09-132032-09-18Us
US9345701No2016-05-242022-05-10Us
US9511066No2016-12-062022-05-10Us
US9555000No2017-01-312023-04-04Us
US9474750No2016-10-252018-12-22Us
US9283221No2016-03-152022-05-10Us
US9480644No2016-11-012035-03-16Us
US9629965No2017-04-252035-03-16Us
US9561177No2017-02-072035-03-16Us
US9468747No2016-10-182035-03-16Us
US9707226No2017-07-182035-03-16Us
US9687454No2017-06-272029-08-07Us
US9724471No2017-08-082027-05-23Us
US9775838No2017-10-032035-03-16Us
US9737669No2017-08-222024-11-23Us
US9855221No2018-01-022022-02-14Us
US9907793No2018-03-062023-04-04Us
US9931305No2018-04-032022-02-14Us
US10085937No2018-10-022035-03-16Us
US10143972No2018-12-042031-05-24Us
US10220158No2019-03-052035-03-20Us
US10143792No2018-12-042031-05-24Us
US10285910No2002-10-112022-10-11Us
US10314977No2004-11-232024-11-23Us
US10322239No2011-02-282031-02-28Us
US10335549No2005-04-302025-04-30Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)200-205 °CNot Available
water solubilitySolubleNot Available
logP2.09HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility5.64 mg/mLALOGPS
logP1.47ALOGPS
logP1.62ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)7.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity88.72 m3·mol-1ChemAxon
Polarizability33.83 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9729
Blood Brain Barrier+0.9787
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8788
P-glycoprotein inhibitor INon-inhibitor0.7922
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8522
CYP450 2D6 substrateSubstrate0.5296
CYP450 3A4 substrateSubstrate0.6107
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9303
CYP450 2D6 inhibitorNon-inhibitor0.7886
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9153
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9523
Ames testNon AMES toxic0.7182
CarcinogenicityNon-carcinogens0.9583
BiodegradationNot ready biodegradable0.9968
Rat acute toxicity2.7231 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7798
hERG inhibition (predictor II)Non-inhibitor0.8641
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0139000000-e70921e0765c3389ce85

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenanthrenes and derivatives
Sub Class
Not Available
Direct Parent
Phenanthrenes and derivatives
Alternative Parents
Isoquinolones and derivatives / Tetralins / Coumarans / 1-hydroxy-2-unsubstituted benzenoids / Alkyl aryl ethers / Aralkylamines / Piperidines / Tertiary alcohols / Trialkylamines / 1,2-aminoalcohols
show 7 more
Substituents
Phenanthrene / Isoquinolone / Tetralin / Coumaran / 1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Aralkylamine / Piperidine / Cyclic alcohol / Tertiary alcohol
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid, organic heteropentacyclic compound (CHEBI:7459)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Narita M, Suzuki M, Mizoguchi H, Narita M, Yajima Y, Sakurada S, Tseng LF, Suzuki T: Up-regulation of mu-opioid receptor-mediated G-protein activation in protein kinase Cgamma knockout mice following repeated naloxone treatment. Neurosci Lett. 2003 Feb 27;338(2):103-6. [PubMed:12566163]
  2. Freye E, Latasch L, Von Bredow G, Neruda B: [The opioid tramadol demonstrates excitatory properties of non-opioid character--a preclinical study using alfentanil as a comparison]. Schmerz. 1998 Feb 28;12(1):19-24. [PubMed:12799988]
  3. Neal CR Jr, Owens CE, Taylor LP, Hoversten MT, Akil H, Watson SJ Jr: Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat. 2003 Jul;25(4):233-47. [PubMed:12842269]
  4. Spetea M, Toth F, Schutz J, Otvos F, Toth G, Benyhe S, Borsodi A, Schmidhammer H: Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci. 2003 Jul;18(2):290-5. [PubMed:12887410]
  5. Marek GJ: Behavioral evidence for mu-opioid and 5-HT2A receptor interactions. Eur J Pharmacol. 2003 Aug 1;474(1):77-83. [PubMed:12909198]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714]
  8. Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70. [PubMed:17918759]
  9. van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32. [PubMed:17367258]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Moncada A, Cendan CM, Baeyens JM, Del Pozo E: Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice. Eur J Pharmacol. 2003 Mar 28;465(1-2):53-60. [PubMed:12650833]
  2. Kakinohana M, Marsala M, Carter C, Davison JK, Yaksh TL: Neuraxial morphine may trigger transient motor dysfunction after a noninjurious interval of spinal cord ischemia: a clinical and experimental study. Anesthesiology. 2003 Apr;98(4):862-70. [PubMed:12657847]
  3. Breljak D, Boranic M, Horvat S: Oligopeptide fragments of the enkephalin molecule interfere with hematopoietic cell colony formation. Int J Immunopathol Pharmacol. 2000 Jan-Apr;13(1):13-19. [PubMed:12749773]
  4. Chudapongse N, Kim SY, Kramer RE, Ho IK: Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells. J Pharmacol Sci. 2003 Nov;93(3):372-5. [PubMed:14646257]
  5. Osman AM, Gomma M, Saad AH: A possible role for an enkephalinergic system in the internal defense mechanism of Biomphalaria alexandrina exposed to Schistosoma mansoni. J Egypt Soc Parasitol. 2003 Dec;33(3):841-61. [PubMed:14708857]
  6. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714]
  7. van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32. [PubMed:17367258]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Peng X, Neumeyer JL: Kappa receptor bivalent ligands. Curr Top Med Chem. 2007;7(4):363-73. [PubMed:17305578]
  2. van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32. [PubMed:17367258]
  3. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35. [PubMed:18354714]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Other/unknown
General Function
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function
Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. Transcript...
Gene Name
CREB1
Uniprot ID
P16220
Uniprot Name
Cyclic AMP-responsive element-binding protein 1
Molecular Weight
36687.86 Da
References
  1. Li J, Li YH, Yuan XR: Changes of phosphorylation of cAMP response element binding protein in rat nucleus accumbens after chronic ethanol intake: naloxone reversal. Acta Pharmacol Sin. 2003 Sep;24(9):930-6. [PubMed:12956944]
  2. Chartoff EH, Papadopoulou M, Konradi C, Carlezon WA Jr: Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum. J Neurochem. 2003 Oct;87(1):107-18. [PubMed:12969258]
  3. Gao C, Chen LW, Tao YM, Chen J, Xu XJ, Chi ZQ: Effects of ohmefentanyl stereoisomers on phosphorylation of cAMP- response element binding protein in cultured rat hippocampal neurons. Acta Pharmacol Sin. 2003 Dec;24(12):1253-8. [PubMed:14653953]
  4. Walters CL, Cleck JN, Kuo YC, Blendy JA: Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron. 2005 Jun 16;46(6):933-43. [PubMed:15953421]
  5. Hawes JJ, Narasimhaiah R, Picciotto MR: Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures. J Neurochem. 2006 Feb;96(4):1160-8. Epub 2006 Jan 17. [PubMed:16417577]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Antagonist
Other/unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K: Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther. 2006 Mar;5(3):611-20. [PubMed:16546975]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transmembrane signaling receptor activity
Specific Function
Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and ...
Gene Name
TLR4
Uniprot ID
O00206
Uniprot Name
Toll-like receptor 4
Molecular Weight
95679.19 Da
References
  1. Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR: (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain. 2012 May;13(5):498-506. doi: 10.1016/j.jpain.2012.02.005. Epub 2012 Apr 20. [PubMed:22520687]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Bencharit S, Morton CL, Xue Y, Potter PM, Redinbo MR: Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol. 2003 May;10(5):349-56. [PubMed:12679808]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fang WB, Chang Y, McCance-Katz EF, Moody DE: Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. J Anal Toxicol. 2009 Oct;33(8):409-17. doi: 10.1093/jat/33.8.409. [PubMed:19874646]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther. 2000 Jul;294(1):73-9. [PubMed:10871297]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]

Drug created on June 13, 2005 07:24 / Updated on October 16, 2019 13:15